Phillips 66 (PSX) Pops 2.86% for February 17

Equities Staff  |

One of the S&P 500’s big winners for Wednesday February 17 was Phillips 66 (PSX) as the company’s stock climbed 2.86% to $80.49 on volume of 3.28 million shares.

The stock opened at $79.09 and saw an intraday low of $78.88 and an intraday high of $80.89. All told, the day saw a per-share gain of $2.24. The stock’s average daily volume of 3.74 million and 533.44 million shares outstanding. Phillips 66 now has a 50-day SMA is $79.54 and 200-day SMA is $80.26, and it has a 52-week high of $94.12 and a 52-week low of $69.79.

Phillips 66 is a downstream energy company. The Company's segment includes Refining and Marketing (R&M), Midstream and Chemicals businesses. Its Chemicals business is conducted through its 50% interest in Chevron Phillips Chemical Company LLC.

Based out of Houston, TX, Phillips 66 has 14,000 employees and, after today’s trading, reached a market cap of $42.94 billion. The stock’s P/E Ratio is 10.1. Its P/S ratio is 0.42, P/B ratio is 1.85, and P/FCF ratio is -34.1.

For a complete fundamental analysis analysis of Phillips 66, check out’s Stock Valuation Analysis report for PSX. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update. Mr. Corin discusses the company's recent acquisition of Metastron, a radiopharmaceutical for cancer bone pain. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need?.

Emerging Growth

The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd through its subsidiary operates as a cannabinoid-based research and development company in Canada.